Perennial Allergic Rhinitis
📧 Sign up to get email alerts when something new happens for Perennial Allergic Rhinitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-02-17Clinical Trial Update: Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181) [Phase 4]
Phase 4 trial comparing preference for Clarinex tablets versus Zyrtec tablets in patients with seasonal and perennial allergic rhinitis has …
-
FDA approval · 2022-01-19FDA Approved: MONTELUKAST — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for Montelukast (generic, Sandoz Inc), updating the product's approval status under the ANDA. Montel…
-
FDA approval · 2022-01-19FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for Montelukast sodium from Rising Pharma Holdings, Inc., enabling changes to its labeling or indica…
-
FDA approval · 2022-01-19FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for Montelukast Sodium from Rising Pharma Holdings, Inc., updating the labeling under an existing ap…
-
FDA approval · 2021-11-01FDA Approved: ASTEPRO ALLERGY — Supplemental Application (Bayer HealthCare LLC.)
FDA approved a supplemental application for AStepro Allergy (azelastine HCl) from Bayer HealthCare LLC, resulting in updated labeling for th…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-10-15FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Torrent Pharmaceuticals Limited)
The FDA approved a supplemental application for Montelukast Sodium from Torrent Pharmaceuticals Limited under an approved ANDA. This action …
-
FDA approval · 2021-06-17FDA Approved: ASTEPRO ALLERGY — Original Application (Bayer HealthCare LLC.)
FDA approved ASTEPRO ALLERGY (azelastine hydrochloride) under Bayer HealthCare LLC.'s original NDA, establishing its intranasal antihistamin…
-
FDA approval · 2021-04-16FDA Approved: DYMISTA — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for DYMISTA (azelastine hydrochloride and fluticasone propionate) submitted by Viatris Specialty LLC…
-
FDA label_change · 2021-02-22FDA Approved: SINGULAIR — Supplemental Application (Organon LLC)
The FDA approved a supplemental application for Singulair (montelukast sodium) filed by Organon LLC, resulting in changes to the product lab…
-
FDA approval · 2021-02-18FDA Approved: AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE — Original Application (Padagis Israel Pharmaceuticals Ltd)
The FDA approved Padagis Israel Pharmaceuticals' azelastine hydrochloride and fluticasone propionate nasal spray as an original ANDA, provid…
-
FDA approval · 2020-11-24FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved Torrent Pharmaceuticals Limited's supplemental application for montelukast sodium. This action grants regulatory approval for c…
-
FDA approval · 2020-10-20FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approved Ajanta Pharma USA Inc.'s supplemental application for Montelukast Sodium, marking approval of a generic montelukast product und…
-
FDA approval · 2020-10-05FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Torrent Pharmaceuticals Limited)
The FDA approved Torrent Pharmaceuticals Limited's supplemental application for montelukast sodium, authorizing the regulatory action for th…
-
FDA approval · 2020-09-04FDA Approved: MONTELUKAST SODIUM — Original Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals' Montelukast Sodium as a generic version of montelukast for the prevention and maintenance treatment of …
-
FDA approval · 2020-08-14FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for Montelukast Sodium from Rising Pharma Holdings, Inc. This action authorizes changes to the p…
-
CLINICAL_TRIALS trial_result · 2020-04-08Clinical Trial Update: Topical Nasal Fluticasone Propionate in the Control of Allergic Rhinitis SymptomsPerene [Phase 3]
Phase 3 trial evaluating topical nasal fluticasone propionate for control of perennial allergic rhinitis completed.
-
CLINICAL_TRIALS trial_result · 2020-03-27Clinical Trial Update: Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis [Phase 3]
Phase 3 trial update on HCP1102 capsule evaluating efficacy and safety in perennial allergic rhinitis.
-
FDA approval · 2019-11-08FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approved Ajanta Pharma USA Inc.'s supplemental application for montelukast sodium.
-
FDA approval · 2019-11-08FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approves Ajanta Pharma USA Inc.'s supplemental application for Montelukast Sodium, updating regulatory status for the product.
-
FDA approval · 2019-11-05FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental ANDA for montelukast sodium from Rising Pharma Holdings, enabling the marketing of a generic montelukast sodium …
-
CLINICAL_TRIALS withdrawal · 2019-10-09Clinical Trial Update: Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis [Phase 3]
Phase 3 non-inferiority study comparing Noex 50µg to Busonid 50µg for allergic rhinitis was withdrawn.
-
FDA approval · 2019-08-09FDA Approved: SINGULAIR — Supplemental Application (Organon LLC)
FDA approved a supplemental application for Singulair (montelukast) by Organon LLC, marking an additional regulatory action for the product.
-
FDA approval · 2019-08-09FDA Approved: SINGULAIR — Supplemental Application (Organon LLC)
The FDA approved a supplemental application for Singulair (montelukast sodium) submitted by Organon LLC.
-
CLINICAL_TRIALS trial_result · 2019-03-18Clinical Trial Update: Efficacy of Allergen Immunotherapy for Allergic Rhinitis in Thais [Phase 4]
Phase 4 clinical trial evaluating efficacy of allergen immunotherapy for perennial allergic rhinitis in Thai patients has completed.
-
FDA approval · 2018-11-21FDA Approved: CLARITIN CHEWABLE GRAPE AND BUBBLEGUM — Supplemental Application (Bayer HealthCare LLC.)
FDA approved a supplemental application to add Claritin Chewable Grape and Bubblegum (loratadine) as a new chewable dosage form, expanding t…